Literature DB >> 16604394

Photodynamic therapy in macular diseases of asian populations: when East meets West.

Wai-Man Chan1, Timothy Y Y Lai, Yasuo Tano, David T L Liu, Kenneth K W Li, Dennis S C Lam.   

Abstract

PURPOSE: We reviewed the indications, safety, and efficacy of photodynamic therapy with verteporfin in various macular diseases and vasculopathies, which are common in Asian populations, and compared the outcomes of photodynamic therapy in Asian patients with the outcomes in Caucasian patients.
METHODS: Relevant clinical and laboratory original articles, case reports, and review articles that have been published in the literature between January 1999 and October 2004 were searched in Medline. The potential differences in the response to photodynamic therapy between Asian and Caucasian patients were evaluated. Articles in foreign languages with English abstracts were included.
RESULTS: Macular diseases commonly seen in Asian populations, including choroidal neovascularization (CNV) of age-related macular degeneration, secondary to pathologic myopia or from an idiopathic cause, and choroidal vasculopathies such as central serous chorioretinopathy and polypoidal choroidal vasculopathy were included in the review. The results were tabulated and the differences with Caucasian populations were compared and highlighted.
CONCLUSION: Photodynamic therapy has been found to be an effective and noninvasive treatment for various subfoveal CNV and choroidal vasculopathies of the macula. Diverse behavior in different ethnic groups is observed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604394     DOI: 10.1007/s10384-005-0259-z

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.211


  70 in total

1.  Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.

Authors:  Roy H Loo; Ingrid U Scott; Harry W Flynn; J Donald M Gass; Timothy G Murray; Mary Lou Lewis; Phillip J Rosenfeld; William E Smiddy
Journal:  Retina       Date:  2002-02       Impact factor: 4.256

Review 2.  Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.

Authors:  U Schmidt-Erfurth; T Hasan
Journal:  Surv Ophthalmol       Date:  2000 Nov-Dec       Impact factor: 6.048

3.  Subretinal surgery for juxtafoveal choroidal neovascularization.

Authors:  Daniel P Joseph; Akinori Uemura; Matthew A Thomas
Journal:  Retina       Date:  2003-08       Impact factor: 4.256

4.  Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy.

Authors:  Christina Canakis; Charalampos Livir-Rallatos; Zafirakis Panayiotis; Gerasimos Livir-Rallatos; Efstratios Persidis; Mandi D Conway; Gholam A Peyman
Journal:  Am J Ophthalmol       Date:  2003-10       Impact factor: 5.258

5.  Central serous chorioretinopathy and indocyanine green angiography.

Authors:  F C Piccolino; L Borgia
Journal:  Retina       Date:  1994       Impact factor: 4.256

6.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.

Authors:  D S C Lam; W-M Chan; D T L Liu; D S P Fan; W W Lai; K K L Chong
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

Review 7.  Polypoidal choroidal vasculopathy.

Authors:  Antonio P Ciardella; Irene M Donsoff; Sheau J Huang; Danielle L Costa; Lawrence A Yannuzzi
Journal:  Surv Ophthalmol       Date:  2004 Jan-Feb       Impact factor: 6.048

8.  Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography.

Authors:  R Levine; A J Brucker; F Robinson
Journal:  Ophthalmology       Date:  1989-06       Impact factor: 12.079

9.  Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors: 
Journal:  Am J Ophthalmol       Date:  2003-12       Impact factor: 5.258

10.  Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series.

Authors:  Wai-Man Chan; Dennis S C Lam; Tak-Hung Wong; Timothy Y Y Lai; Alvin K H Kwok; Barbara S M Tam; Kenneth K W Li
Journal:  Ophthalmology       Date:  2003-12       Impact factor: 12.079

View more
  16 in total

1.  CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration.

Authors:  Daisuke Imai; Keisuke Mori; Kuniko Horie-Inoue; Peter L Gehlbach; Takuya Awata; Satoshi Inoue; Shin Yoneya
Journal:  J Ocul Biol Dis Infor       Date:  2010-07-28

Review 2.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

Review 3.  Treatment of age-related macular degeneration: beyond VEGF.

Authors:  Joan W Miller
Journal:  Jpn J Ophthalmol       Date:  2010-12-30       Impact factor: 2.447

4.  Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): results of the Japanese AMD Trial (JAT) extension.

Authors:  Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2008-04-30       Impact factor: 2.447

5.  Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration.

Authors:  Koko Saito; Teiko Yamamoto; Daijiro Tsuchiya; Ryo Kawasaki; Shion Haneda; Hidetoshi Yamashita
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

6.  Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients.

Authors:  Suk Ho Byeon; Sung Chul Lee; Hyun-Sub Oh; Sung Soo Kim; Hyoung Jun Koh; Oh Woong Kwon
Journal:  Jpn J Ophthalmol       Date:  2008-03-28       Impact factor: 2.447

7.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Yoko Matsumoto; Shiho Kashiwakura; Kyoko Fujita; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

8.  Photodynamic therapy for age-related macular degeneration in Japanese patients: results after one year.

Authors:  Tetsuo Ogino; Muneyasu Takeda; Hiroko Imaizumi; Utako Okushiba
Journal:  Jpn J Ophthalmol       Date:  2007-06-07       Impact factor: 2.447

Review 9.  Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.

Authors:  Francesco Sartini; Michele Figus; Marco Nardi; Giamberto Casini; Chiara Posarelli
Journal:  Eye (Lond)       Date:  2019-03-01       Impact factor: 3.775

10.  Multifocal photodynamic therapy for diffuse choroidal hemangioma.

Authors:  Marcus Ang; Shu-Yen Lee
Journal:  Clin Ophthalmol       Date:  2012-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.